.: ORİJİNAL ARAŞTIRMA
Effect of the COVID-19 Pandemic on the Diagnosis of Non-Melanoma Skin Cancers: A Retrospective Case Control Study
COVID-19 Pandemisinin Nonmelanom Deri Kanserleri Tanısı Üzerindeki Etkisi: Retrospektif Vaka Kontrol Çalışması
Turkiye Klinikleri J Dermatol. 2022;32(1):29-36
doi: 10.5336/dermato.2021-86251
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: The coronavirus disease-2019 (COVID-19) pandemic has caused delays in the diagnosis and treatment of some oncological diseases. This study aimed to reveal the effect of the COVID-19 pandemic on the frequency of diagnosis of non-melanoma skin cancers (NMSC) and the demographic characteristics of patients. Material and Methods: Patients aged over 18 years, who were histopathologically diagnosed with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) between March 12, 2019 and March 11, 2021 were included in the study. The demographic characteristics of these patients, the number of total skin biopsies, and the number of BCC and SCC biopsies were compared between the pre-pandemic and pandemic periods, based on the date of March 12, 2020, when the pandemic measures began to be implemented in Turkey. Results: With the pandemic, there was a 26.7% decrease in the total skin biopsies and a 21% decrease in the total NMSC biopsies. Despite a 34% decrease in the number of biopsies for the diagnosis of BCC, a 15.8% increase was observed in the number of biopsies for the diagnosis of SCC. The frequency of excisional biopsies was observed to increase among the patients with BCC and SCC during the pandemic period (p=0.004 and p=0.001, respectively). Conclusion: The number of total skin biopsies and total NMSC biopsies significantly decreased during the pandemic period. The health system should be reorganized to effectively handle pandemics and similar crisis periods, and new strategies should be determined regarding patient education, early diagnosis, and treatment approaches for NMSC.
Keywords: Basal cell carcinoma; COVID-19; pandemics; skin neoplasms; squamous cell carcinoma
Objective: The coronavirus disease-2019 (COVID-19) pandemic has caused delays in the diagnosis and treatment of some oncological diseases. This study aimed to reveal the effect of the COVID-19 pandemic on the frequency of diagnosis of non-melanoma skin cancers (NMSC) and the demographic characteristics of patients. Material and Methods: Patients aged over 18 years, who were histopathologically diagnosed with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) between March 12, 2019 and March 11, 2021 were included in the study. The demographic characteristics of these patients, the number of total skin biopsies, and the number of BCC and SCC biopsies were compared between the pre-pandemic and pandemic periods, based on the date of March 12, 2020, when the pandemic measures began to be implemented in Turkey. Results: With the pandemic, there was a 26.7% decrease in the total skin biopsies and a 21% decrease in the total NMSC biopsies. Despite a 34% decrease in the number of biopsies for the diagnosis of BCC, a 15.8% increase was observed in the number of biopsies for the diagnosis of SCC. The frequency of excisional biopsies was observed to increase among the patients with BCC and SCC during the pandemic period (p=0.004 and p=0.001, respectively). Conclusion: The number of total skin biopsies and total NMSC biopsies significantly decreased during the pandemic period. The health system should be reorganized to effectively handle pandemics and similar crisis periods, and new strategies should be determined regarding patient education, early diagnosis, and treatment approaches for NMSC.
Keywords: Basal cell carcinoma; COVID-19; pandemics; skin neoplasms; squamous cell carcinoma
ÖZET
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisi bazı onkolojik hastalıkların tanı ve tedavisinde gecikmelere neden olmuştur. Bu çalışmada, COVID-19 pandemisinin melanom dışı deri kanserleri (MDDK) tanı sıklığı ve hastaların demografik özellikleri üzerindeki etkisini ortaya koymak amaçlandı. Gereç ve Yöntemler: 12 Mart 2019-11 Mart 2021 tarihleri arasında histopatolojik olarak bazal hücreli karsinom (BHK) ve skuamöz hücreli karsinom (SHK) tanısı almış 18 yaş üstü hastalar çalışmaya dâhil edildi. Türkiye'de pandemi tedbirlerinin başlandığı 12 Mart 2020 tarihi baz alınarak, pandemi öncesi ve pandemi dönemindeki total deri biyopsisi, BHK ve SHK biyopsi sayıları ve bu hastaların demografik özellikleri karşılaştırıldı. Bulgular: Pandemi ile beraber total deri biyopsisi işlemlerinde %26,7, total MDDK biyopsi işlemlerinde ise %21 oranında azalma izlendi. BHK tanısı için yapılan biyopsi oranında %34 oranında bir azalmaya karşın SHK tanısı için yapılan biyopsi oranında %15,8 oranında artış görüldü. Pandemi döneminde BHK ve SHK hastalarında eksizyonel biyopsi sıklığında artış izlendi (sırasıyla p=0,004 ve p=0,001). Sonuç: Pandemi döneminde total deri biyopsi sayısı ve MDDK biyopsi sayısı önemli ölçüde azalmıştır. Pandemi ve benzeri kriz dönemlerine ilişkin, sağlık sisteminde yeniden düzenlemeler yapılmalı ve MDDK'ye yönelik hasta eğitimi, erken tanı ve tedavi yaklaşımları ile ilgili yeni stratejiler belirlenmelidir.
Anahtar Kelimeler: Bazal hücreli karsinom; COVID-19; pandemiler; deri tümörleri; skuamöz hücreli karsinom
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisi bazı onkolojik hastalıkların tanı ve tedavisinde gecikmelere neden olmuştur. Bu çalışmada, COVID-19 pandemisinin melanom dışı deri kanserleri (MDDK) tanı sıklığı ve hastaların demografik özellikleri üzerindeki etkisini ortaya koymak amaçlandı. Gereç ve Yöntemler: 12 Mart 2019-11 Mart 2021 tarihleri arasında histopatolojik olarak bazal hücreli karsinom (BHK) ve skuamöz hücreli karsinom (SHK) tanısı almış 18 yaş üstü hastalar çalışmaya dâhil edildi. Türkiye'de pandemi tedbirlerinin başlandığı 12 Mart 2020 tarihi baz alınarak, pandemi öncesi ve pandemi dönemindeki total deri biyopsisi, BHK ve SHK biyopsi sayıları ve bu hastaların demografik özellikleri karşılaştırıldı. Bulgular: Pandemi ile beraber total deri biyopsisi işlemlerinde %26,7, total MDDK biyopsi işlemlerinde ise %21 oranında azalma izlendi. BHK tanısı için yapılan biyopsi oranında %34 oranında bir azalmaya karşın SHK tanısı için yapılan biyopsi oranında %15,8 oranında artış görüldü. Pandemi döneminde BHK ve SHK hastalarında eksizyonel biyopsi sıklığında artış izlendi (sırasıyla p=0,004 ve p=0,001). Sonuç: Pandemi döneminde total deri biyopsi sayısı ve MDDK biyopsi sayısı önemli ölçüde azalmıştır. Pandemi ve benzeri kriz dönemlerine ilişkin, sağlık sisteminde yeniden düzenlemeler yapılmalı ve MDDK'ye yönelik hasta eğitimi, erken tanı ve tedavi yaklaşımları ile ilgili yeni stratejiler belirlenmelidir.
Anahtar Kelimeler: Bazal hücreli karsinom; COVID-19; pandemiler; deri tümörleri; skuamöz hücreli karsinom
REFERANSLAR:
- Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-80. [Crossref] [PubMed]
- Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare (Basel). 2017;5(4):82. [Crossref] [PubMed] [PMC]
- Wang DM, Morgan FC, Besaw RJ, Schmults CD. An ecological study of skin biopsies and skin cancer treatment procedures in the United States Medicare population, 2000 to 2015. J Am Acad Dermatol. 2018;78(1):47-53. [Crossref] [PubMed]
- Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol. 2020;18(3):123. [Crossref] [PubMed] [PMC]
- WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. Brazilian Journal of Implantology and Health Sciences. 2020;2(3). [Link]
- Cakir B. COVID-19 in Turkey: lessons learned. J Epidemiol Glob Health. 2020;10(2):115-7. [Crossref] [PubMed] [PMC]
- Rosenbaum L. The untold toll-the pandemic's effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368-71. [Crossref] [PubMed]
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199-207. [Crossref] [PubMed] [PMC]
- Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750-1. Erratum in: Lancet Oncol. 2020. [Crossref] [PubMed] [PMC]
- Eisemann N, Waldmann A, Geller AC, Weinstock MA, Volkmer B, Greinert R, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014;134(1):43-50. [Crossref] [PubMed]
- Iannacone MR, Green AC. Towards skin cancer prevention and early detection: evolution of skin cancer awareness campaigns in Australia. Melanoma Manag. 2014;1(1):75-84. [Crossref] [PubMed] [PMC]
- Tejera-Vaquerizo A, Nagore E. Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model. J Eur Acad Dermatol Venereol. 2020;34(8):e351-e3. [Crossref] [PubMed] [PMC]
- Ricci F, Fania L, Paradisi A, Di Lella G, Pallotta S, Sobrino L, et al. Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown. J Eur Acad Dermatol Venereol. 2020;34(12):e778-e9. [Crossref] [PubMed] [PMC]
- Asai Y, Nguyen P, Hanna TP. Impact of the COVID-19 pandemic on skin cancer diagnosis: A population-based study. PLoS One. 2021; 16(3):e0248492. [Crossref] [PubMed] [PMC]
- Abbassi O, Waseem S, Murphy S, Roszpopa J, Nizamoglu M, Patel AJK, et al. Non-mela noma skin cancer activity during the COVID-19 pandemic- A single UK tertiary centre experience. JPRAS Open. 2021. [Crossref] [PubMed] [PMC]
- Marson JW, Maner BS, Harding TP, Meisenheimer J VII, Solomon JA, Leavitt M, et al. The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers. J Am Acad Dermatol. 2021;84(4): 1100-3. [Crossref] [PubMed] [PMC]
- Capitelli-McMahon H, Hurley A, Pinder R, Matteucci P, Totty J. Characterising non-melanoma skin cancer undergoing surgical management during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg. 2021;74(3):644-710. [Crossref] [PubMed] [PMC]
- Luo GG, Ou JH. Oncogenic viruses and cancer. Virol Sin. 2015;30(2):83-4. [Crossref] [PubMed] [PMC]
- Barton V, Armeson K, Hampras S, Ferris LK, Visvanathan K, Rollison D, et al. Nonmelanoma skin cancer and risk of all-cause and cancer-related mortality: a systematic review. Arch Dermatol Res. 2017;309(4):243-51. [Crossref] [PubMed] [PMC]
- Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112 Suppl 1(Suppl 1):S92-107. [Crossref] [PubMed] [PMC]
- Renzi C, Mastroeni S, Passarelli F, Mannooranparampil TJ, Caggiati A, Potenza C, et al. Factors associated with large cutaneous squamous cell carcinomas. J Am Acad Dermatol. 2010;63(3):404-11. [Crossref] [PubMed]
- Nahm SH, Rembielak A, Peach H, Lorigan PC; Contributing Clinicians. Consensus guidelines for the management of melanoma during the COVID-19 pandemic: surgery, systemic anti-cancer therapy, radiotherapy and follow-up. Clin Oncol (R Coll Radiol). 2021;33(1):e54-e7. [Crossref] [PubMed] [PMC]
- Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41(1):69-71. [Crossref] [PubMed]
.: İşlem Listesi